• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to a liquid pharmaceutical composition, in particular for producing an infusion solution containing alprostadil as active ingredient, dissolved in a nonaqueous solvent containing at least one acid or acting as an acid or proton donating substance as a stabilizer.
    公开号:AT515356A1
    申请号:T50063/2014
    申请日:2014-01-30
    公开日:2015-08-15
    发明作者:
    申请人:Gebro Holding Gmbh；
    IPC主号:
    专利说明:

    Stable alcoholic solution of alprostadil
    Alprostadil (PGE1) is a substance described in the European Pharmacopoeia from the group of prostaglandin analogues. It is identical to the body's own prostaglandin E1. Its main physiological effects are vasodilation and inhibition of platelet aggregation. From this profile of action, the most important indications are the treatment of erectile dysfunction, the treatment of peripheral arterial disease and the short-term treatment of certain neonatal heart defects. As pharmaceutical dosage forms are mainly parenteral, for the treatment of erectile dysfunction and topical dosage forms available.
    Alprostadil is a chemically extremely unstable drug. The commentary of the European Pharmacopoeia called the elimination of water to prostaglandin Ai (PGA1) as the most important degradation reaction. This degradation product is referred to in the monograph of the European Pharmacopoeia as impurity A. It may further react in an isomerization reaction to prostaglandin Bi, which is referred to as Contamination B in the European Pharmacopoeia monograph. Overall, the European Pharmacopoeia names eleven impurities with their respective molecular structure. According to the comment of the European Pharmacopoeia, the initial reaction of the degradation, namely the elimination of water to PGA1, takes place particularly easily under acidic or basic conditions, with divalent and trivalent cations additionally impairing the stability in ethanolic solution.
    Because of the instability of the active ingredient, it is not possible to produce ready-to-use parenteral preparations which have sufficient storage stability for marketing. Alprostadil for parenteral use is therefore offered exclusively in the form of concentrates, which are diluted or reconstituted shortly before use by dissolution in a suitable sterile solution (for example physiological saline) to the ready-to-use infusion solution. The concentrates used are essentially either lyophilisates or nonaqueous solutions.
    Lyophilisates are solid, powdery concentrates which are prepared by freeze-drying the active ingredient together with stabilizing auxiliaries. The manufacturing process is complex and expensive; The lyophilisate is packaged either in vials or more user friendly in dual-chamber syringes or dual chamber cartridges and can be stored at room temperature. The stabilizing adjuvant used is mainly alpha-cyclodextrin (Alfadex). Trade names of such products are e.g. Caverject® (Pfizer, Pharmacia), Prostavasin® (UCB Pharma) or Viridal® (UCB Pharma). CN 102688203 describes a lyophilizate containing alprostadil in which a mixture of dextran and hydroxypropyl-beta-cyclodextrin is used for stabilization.
    Essentially solutions of the active ingredient in absolute ethanol are used as non-aqueous solutions. These ethanolic concentrates must be constantly stored at low temperatures of 2 to 8 ° C. The maintenance of the cold chain and the proof of compliance represent a considerable expense for the manufacturers and users of the products and cause high costs. Nevertheless, the period of use of the preparations is typically only 18 months. Trade names of these products are e.g. Pridax® (Gebro, Pharmore), Alprestil® (Gebro), Miniprog® (Pfizer, Pharmacia) or Alprostadil "PINT "® (Pint Pharma).
    Oily and liposomal preparations and concentrates are also described in the literature. The latter are used in Japan e.g. also marketed under the brand names Liple® (Tanabe) and Palux® (Taisho).
    The stability of semi-solid preparations is limited even under the most favorable conditions to a few months, which greatly limits the practical use of such products, especially in the indication of erectile dysfunction. Topical formulations are pure lipogels which include natural oils, fatty acids, fatty alcohols or synthetic lipids, e.g. Isopropyl myristate, and in addition with thickening agents, e.g. Poloxamers, can be thickened. Described are such lipogel e.g. in KR 20010011625 and JP 0383925.
    Other dosage forms, e.g. Solid sticks for use in the urethra are e.g. offered under the brand name Muse® by Abbott. For the present invention, the solution of the active ingredient in absolute ethanol (eg Pridax® 20 pg / ml concentrate for solution for infusion) represents the closest prior art. The main advantage of the ethanolic solution is that they are easier to process into a solution ready for infusion Can be used as a lyophilisate. The lyophilisate must first be reconstituted in a first step in the vial with a suitable solvent; then this solution must be in a second
    Step of the infusion solution can be added. In contrast, the ampoule can be added directly in one step to an infusion solution. This simplification of handling also reduces the risk of manipulation errors and the risk of introducing germs.
    Another advantage of the ethanolic solution is the very simple composition of the formulation consisting solely of the active ingredient and the solvent. It allows a much simpler and cheaper compared to a lyophilizate production.
    Another advantage is that the simple composition of the formulation substantially facilitates the analysis of the preparation. Due to the low dosage of the active ingredient, quality controls must be used to quantify impurities down to a concentration range of 10 ng / ml. At such low concentrations, it is a great advantage if the preparation is directly analyzable without processing and without separation of excipients.
    A disadvantage of the ethanolic solution is its low chemical stability. It has the following specific adverse effects: • High concentrations of degradation products in the finished product must be accepted (eg 6% PGA1) • The running time of the finished products is limited (eg 18 months) • The storage of the finished products must be done cool, a permanent cold chain is to be maintained (2 ° C - 8 ° C) • The service life at room temperature, which is unavoidable in the course of the manufacturing process, must be limited to a few hours.
    There is therefore a great interest in providing a, preferably ethanolic, alprostadil solution which is still easy to use, which can be prepared simply and inexpensively, and which is straightforward to analyze but at the same time has improved stability. The object of the invention is therefore to develop such a formulation which, in addition to the previous advantages of the ethanolic solution (eg from Pridax®), contains a lower concentration of degradation products, has a longer shelf life and a less severe cooling regime during production, during transport and required during storage.
    This object is achieved in that the solution of alprostadil contains a small amount of an acidic component.
    In this case, it is provided in particular to add to the alprostadil solution the amount of the acidic component required for the stabilization in the form of an organic acid and to fill the solution thus stabilized in glass ampoules or glass vials. Surprisingly, it has been found that the solution according to the invention, in comparison with the prior art (Pridax® 20 pg / ml concentrate for the preparation of an infusion solution), has a substantially better storage stability, in particular that the formation of the main degradation product PGA1 is markedly slowed down. This stabilizing effect is so pronounced that the preparation according to the invention is suitable for achieving all the objectives of the invention. The upper specification limit for the degradation product PGA1 can be reduced (e.g., from 6% to 4%). The shelf life of the product is prolonged (e.g., from 18 months to 36 months). The service life of the solution during the preparation at room temperature is increased (for example, from 4 to 8 hours), whereby the batch size can be increased. The analytical method for the preparation is not complicated by the addition of the acidic component.
    From the literature (Vieillard et al., Pharmaceutical Anal Acta 2013, 4: 4, 4.00-1488 Alprostadil Comment to Ph. Eur. 4.00) it is known that the active substance alprostadil is very sensitive to bases, acids and oxidizing agents, in particular bases and acids accelerate the elimination of water to the main degradation product PGA1. Because of the low dosage of alprostadil in the concentrate solution from 20 pg / ml to 500 pg / ml, it is to be expected that even small amounts of the above-mentioned impurities lead to a deterioration in the stability. Because of their ubiquitous occurrence is a consistent avoidance of these impurities with the current state of the art, only through the litigation and the purity of packaging materials and solvents not possible or such technologies would increase the production costs to the extent that the product is no longer offered at a market price could be. Quite surprisingly, contrary to the opinion expressed in the literature, it has been found that very small amounts of organic or inorganic acids do not lead to the expected deterioration in stability, but on the contrary to a substantial improvement. For the purposes of the invention, very small amounts of organic or inorganic acids are amounts which are of the same order of magnitude as the amount of the active ingredient used in the solution.
    According to the state of the art, the concentration of the active substance in ethanolic alprostadil solutions is given in the unit pg / ml. By analogy with this, the concentration of the acid in the unit μ9 / ιπΙ is given in this invention. A conversion to the unit pg / g can be made at any time by dividing by the density of the solvent (absolute alcohol about 0.789 g / ml). In the formulations according to the invention low acid concentrations of 5 - 500 μ9 / ιηΙ be used, preferably those between 5-50 pg / ml. In a particularly preferred embodiment of the invention, an acid addition of likewise 20 μ 9 / πιΙ is provided for stabilizing an ethanolic solution containing 20 pg / ml alprostadil.
    For analytical determination of the artificially added acid, prior art analytical methods such as e.g. HPLC, GC, titration or spectroscopic methods are used. Detection of the addition of acid by measurement of the pH in the alcoholic, i. non-aqueous formulations not possible. In a simplified test, however, acid can be added by diluting the finished medicinal product at a ratio of 1:25 with a 0.9% NaCl solution and then measuring the pH of the two solutions. A decrease of the pH value by at least 0.2 log steps compared to the starting value of the 0.9% NaCl solution used indicates the addition of acid in the formulation.
    For the purposes of the invention, the terms "acidic component" and "acid" are understood as meaning compounds according to the acid definition of Brönsted and Lowry, i. H. Substances that are able to release protons or act as proton donors. These may be both inorganic and organic substances. The acids can be both monobasic and polybasic. Advantageously suitable acids in the context of the invention are those organic and inorganic acids which can be used in parenteral drugs because of their toxicological profile and which dissolve completely and clearly in the concentrations according to the invention in the solvents used, in particular in absolute alcohol, even at low temperatures , Examples of such acids are hydrochloric acid, acetic acid, citric acid, malic acid, lactic acid, tartaric acid or acetylcysteine.
    Stability tests have shown that the extent of stability improvement depends significantly on the type of acid used. Polybasic organic acids have proven to be particularly suitable in the spirit of the invention. Preferably, therefore, acids such as e.g. Citric acid, malic acid or tartaric acid used, particularly preferred is the use of malic acid.
    By the term " non-aqueous solvent " In the present case, solvents are understood to mean, which do not predominantly consist of water or hardly contain water. However, small quantities or residual amounts of water up to a few% by weight may be present.
    According to the prior art, the solvent used is absolute (100%) ethanol. Absolute ethanol without further additives is also the preferred solvent for the purposes of the invention. Experimentally, no deterioration of stability could be detected by the addition of 0.1% water. As a solvent according to the invention therefore also ethanol with a water content of 0-4%, preferably understood with a water content of 0-0.1%. In addition, as a solvent, other substances can be used alone or as an additive to ethanol, which are applicable in parenteral preparations due to their toxicological profile and in which the active ingredient alprostadil is soluble in sufficient concentration. Examples of this are e.g. also propylene glycol or ethyl acetate. In addition, the solvent may also be added to solubilizers such as polyethylene glycol or polysorbate.
    The filling of the solution according to the invention takes place in suitable primary packaging. In this context, the term primary packaging means packaging means which are in direct contact with the drug. On the one hand, they must comply with the requirements of the relevant pharmacopoeias and, moreover, they must be selected in such a way that they minimize as little as possible substances which are detrimental to the stability of the contents, e.g. basic impurities. Suitable materials from which usable for sensitive parenterals primary packaging means are known in the art. Conceivable, for example, but not limited to tubular glass or glass of hydrolytic class I or hydrolytic class II, with internal coating. Also applicable, for example, but not exclusively plastics such as COP, COC, PP, PE, HDPE, Teflon, PA.
    Preferred primary containers are glass ampoules or vials consisting of tubular glass of the hydrolytic class I. As the primary closure material for vials, stoppers of bromobutyl rubber or chlorobutyl rubber, preferably coated, are suitable. Other possible primary containers include, but are not limited to, carpules or prefilled syringes.
    For the purposes of the invention, the acid is preferably added to the solvent during the preparation process of the finished medicinal product. Possible embodiments would be to add the acid during the production process of the solvent or another excipient or during the production process of the active ingredient alprostadil.
    Examples:
    In the following, the invention will be illustrated with reference to some exemplary but non-limiting exemplary embodiments:
    Example 1: (laboratory batch / ethanol / 20 pg / ml alprostadil / 20 pg / ml acetic acid / vials)
    In a 2.5 l glass reactor with stirrer, ethanol is added completely and acetic acid added anhydrous. After complete dissolution, the active ingredient alprostadil is added with stirring, the solution filled in 2 ml Type I amber glass vials and sealed with a chlorobutyl rubber stopper.
    Example 2: (Laboratory batch / ethanol / 20 μg / ml alprostadil / 20 μg / ml malic acid / vials)
    In a 2.5 l glass reactor with stirrer, ethanol is added completely and DL-malic acid is added. After complete dissolution, the active ingredient alprostadil is added with stirring, the solution filled in 2 ml Type I amber glass vials and sealed with a chlorobutyl rubber stopper.
    Example 3: (Laboratory batch / ethanol / 20 μg / ml alprostadil / 20 μg / ml malic acid / pre-filled syringes)
    In a 2.5 l glass reactor with stirrer, ethanol is added completely and DL-malic acid is added. After complete dissolution, the drug alprostadil is added with stirring and the solution filled into pre-filled syringes.
    Example 4: (Production batch / ethanol / 20 pg / ml alprostadil / 20 pg / ml DL-malic acid / ampoules)
    The formulation of Example 4 represents a particularly preferred embodiment of the invention.
    In a 20 l glass reactor with stirrer cooled ethanol is submitted to absolute and added DL-malic acid. After complete dissolution, the drug alprostadil is added with stirring. After complete dissolution of the active ingredient, the solution is filtered through a sterile filter with a pore size of 0.2 pm and filled under aseptic conditions into 2 ml Type I amber glass ampoules. The filled ampoules are checked for visible particles and leaks, labeled and packed secondarily.
    Further embodiments are listed in the following Table 1, wherein in each case only the additives to the solvent in the unit pg / ml are given. All examples listed in the table can be produced in any batch size and filled into all types of suitable packaging.
    Table 1: Formulation examples
    Proof of the stabilizing effect of the added acid:
    The proof of the stabilizing effect of the acid addition was carried out by means of stability tests at the prescribed storage temperature of 4 ° C and under stress conditions at 25 ° C / 65% RH. 2 ml vials of hydrolytic class I tube glass were used as packaging. This glass quality is identical to the glass quality for ampoules. In the following, only the results of the tests at 25 ° C are reported, since these tests permit statements on differences in stability after a shorter storage period. From long-term stability tests of the commercial product Pridax® 20 (Pridax 20 pg / ml concentrate for solution for infusion) it is known that the degradation reactions in the preparation at 4 ° C qualitatively proceed in the same manner as at 25 ° C, but about the factor 10 slower.
    In a first experiment constituting this invention, the control of the formulation of the commercial product Pridax® 20 pg / ml concentrate for solution for infusion (sample designation X03 130002-3), which is to be regarded as the closest prior art, against a test formulation according to the invention 20 pg / ml acetic acid and with otherwise identical composition (sample designation X03 130002-9), tested.
    The content of PGE1 is measured in the unit (pg / ml). In all subsequent results tables, the content is given in% of the starting value of PGE1 for better comparability. The concentration of the degradation product PGA1 is measured and expressed in percent by mass (% m / m) based on the declared content of PGE1.
    Table 2 below shows the contents of PGE1 (active ingredient) and PGA1 (degradation product) for both formulations, in each case directly after preparation (t = 0) and after storage for 12 weeks at 25 ° C./65% RH (t = 12%) ). The absolute values of PGE1 immediately after preparation were 18.3 pg / ml for the acid-free formulation and 18.4 pg / ml for the acetic acid-containing formulation.
    Table 2:
    Control vs 20 pg / ml acetic acid, storage 12 wk at 25 ° C
    The addition of 20 pg / ml acetic acid to the alprostadil solution according to the prior art leads after 12 weeks storage at 25 ° C to a significant stabilizing effect, recognizable by a significantly lower decrease in the content of PGE1 (alprostadil active ingredient) and at a significantly lower Increase in the content of PGA1 (alprostadil degradation product).
    Proof of the influence of the amount of added acid:
    In a further experiment, the influence of the amount of acetic acid on the stabilization effect found was investigated. For this purpose, the formulation of the commercial product Pridax® 20 pg / ml concentrate for the preparation of an infusion solution (sample name X03 130007) against test formulations containing 5 ug / ml, 20 ug / ml and 50 ug / ml acetic acid and with otherwise identical composition (sample designations X03 130007 -1, X03 130007-2 and X03 130007-1), tested.
    Table 3 below and the associated graph 1 show for these four formulations the contents of PGE1 (active ingredient) and PGA1 (degradation product), in each case directly after preparation (t = 0) and after storage for 6 weeks at 25 ° C./65% RH (t = 6w). The absolute values of PGE1 immediately after preparation were between 20.0 and 20.2 pg / ml.
    Table 3:
    Control vs acetic acid in different concentrations, storage 6 wk at 25 ° C
    Graphic 1:
    Control vs acetic acid in different concentrations, storage 6 wk at 25 ° C
    The stabilizing effect of the addition 20 pg / ml acetic acid to the Alprostadil solution could be reproduced in this experiment by means of the sample X03 130007-2. The increase in the amount of acetic acid to 50 pg / ml led to a further improvement in stability, at a concentration of only 5 pg / ml, no significant stabilizing effect could be observed.
    Detection Type of acid addition:
    In a further experiment, the stabilizing effect of various acids at a constant acid addition of each additional 20 pg / ml was investigated comparatively. For this purpose, the formulation of the commercial product Pridax® 20 pg / ml concentrate for solution for infusion (sample designation X03 130007) was compared with test formulations containing in each case 20 pg / ml acetic acid (sample designation X03 130007-2), malic acid (designation X03 130007-5), tartaric acid (Designation X03 130007-8), citric acid (designation X03 130007-11) and acetylcysteine (designation X03 130007-14) and tested otherwise with the same composition.
    The following Table 4 and the associated graph 2 show for these six formulations the levels of PGE1 (active ingredient) and PGA1 (degradation product), in each case directly after preparation (t = 0) and after storage for 6 weeks at 25 ° C / 65% RH (t = 6w). The absolute values of PGE1 immediately after preparation were between 20.0 and 20.3 pg / ml.
    Table 4:
    Control vs 20 μg / ml of various acids, storage 6 hours at 25 ° C
    Graphic 2:
    Control vs 20 pg / ml of various acids, storage 6 wk at 25 ° C
    The experiment shows that the stabilizing effect of the acid addition depends in its extent on the type of acid used. The acetic acid used first has a lower stabilizing effect than polyvalent organic acids and acetylcysteine. For the functional mechanism of the stabilizing effect, this means that it is not just a nonspecific optimization of the acid concentration, analogous to the pH optimization in an aqueous system, but that, surprisingly, an acid-specific stabilization mechanism can be observed.
    Detection amount of malic acid:
    Since malic acid proved to be particularly suitable in the comparison of the different acids and since malic acid is very well suited for use in parenteral preparations because of its toxicological profile, the influence of the amount of malic acid on the stabilization effect found was investigated in a further experiment. For this purpose - analogous to the experiment described above with acetic acid - the formulation of the commercial product Pridax® 20 pg / ml concentrate for solution for infusion (sample designation X03 130007) against test formulations containing 5 pg / ml, 20 pg / ml and 50 pg / ml DL -Malic acid and with otherwise identical composition (sample designations X03 130007-4, X03 130007-5 and X03 130006-1), tested.
    The following Table 5 and the associated graph 3 show for these four formulations the levels of PGE1 (active ingredient) and PGA1 (degradation product), in each case directly after preparation (t = 0) and after storage for 6 weeks at 25 ° C / 65% RH (t = 6w). The absolute values of PGE1 immediately after preparation were between 20.0 and 20.1 pg / ml.
    Table 5:
    Control vs malic acid in different concentrations, storage 6 wk at 25 ° C
    Graphic 3:
    Control vs malic acid in different concentrations, storage 6 wk at 25 ° C
    The experiment shows that malic acid, in contrast to acetic acid, significantly stabilizes alprostadil even at the very low addition of 5 pg / ml. An increase in the acid addition to 20 pg / ml leads to an improvement in the stabilizing effect, while a further increase to 50 pg / ml, in contrast to acetic acid, leads to no further improvement in the stability.
    权利要求:
    Claims (17)
    [1]
    1. A liquid pharmaceutical composition, in particular for the production of an infusion solution containing alprostadil as active ingredient, dissolved in a non-aqueous solvent containing at least one acid or acting as an acid or proton donating substance as a stabilizer.
    [2]
    2. A liquid pharmaceutical composition according to claim 1, consisting of alprostadil as active ingredient, dissolved in a non-aqueous solvent, and of at least one acid or an acid-acting substance as a stabilizer.
    [3]
    3. Composition according to one of claims 1 to 2, characterized in that the solvent is ethanol with a maximum water content up to 4 wt .-%, in particular up to 0.1 wt .-%, based on the ethanol.
    [4]
    4. Composition according to one of claims 1 to 3, characterized in that the solvent is absolute ethanol (100%).
    [5]
    5. Composition according to one of claims 1 to 4, characterized in that the acid is an organic acid, preferably a hydroxycarboxylic acid.
    [6]
    6. The composition according to any one of claims 1 to 5, characterized in that the acid is an acid from the group of hydrochloric acid, malic acid, acetic acid, tartaric acid, lactic acid, acetylcysteine or citric acid.
    [7]
    Composition according to any one of Claims 1 to 6, characterized in that the acid is a polyvalent organic acid, preferably citric acid, malic acid or tartaric acid.
    [8]
    Composition according to any one of Claims 1 to 7, characterized in that the acid is acetylcysteine.
    [9]
    9. Composition according to one of claims 1 to 8, characterized in that the acid is malic acid, in particular DL-malic acid.
    [10]
    10. The composition according to any one of claims 1 to 9, characterized in that the acid in an amount of 1-100, preferably 5-50 pg / ml, in particular 20-50 pg / ml is included.
    [11]
    11. The composition according to any one of claims 1 to 10, characterized in that DL-malic acid in an amount of 1-50, preferably 5-20 pg / ml, is included.
    [12]
    12. The composition according to any one of claims 1 to 11, characterized in that alprostadil in an amount of 1-100, preferably 5-50 pg / ml, in particular 20-50 pg / ml is included.
    [13]
    13. The composition according to any one of claims 1 to 12, characterized in that it is filled into glass ampoules, glass vials, cartridges or prefilled syringes
    [14]
    14. The composition according to any one of claims 1 to 13, characterized in that the pharmaceutical composition is an infusion solution for parenteral administration or can be prepared to an infusion solution.
    [15]
    15. Ready-to-use parenteral composition prepared by diluting the composition according to one of the preceding claims with isotonic, aqueous solution, preferably with physiological saline, in particular in a ratio of 1:10 to 1: 500, preferably 1:20 to 1: 250.
    [16]
    16. A process for the preparation of a liquid pharmaceutical composition according to any one of the preceding claims, characterized in that the dissolved in a nonaqueous solvent active substance alprostadil at least one acid or acting as an acid or proton donating substance is added as a stabilizer.
    [17]
    17. Use of at least one acid or a substance acting as an acid or proton donor substance as a stabilizer for a liquid pharmaceutical composition containing the dissolved in a non-aqueous solvent active ingredient alprostadil.
    类似技术:
    公开号 | 公开日 | 专利标题
    DE4340781C3|2000-01-27|Liquid preparations containing cyclosporin and process for their preparation
    DE69734742T2|2006-07-27|Pharmaceutical compositions containing ascomycin derivatives
    DE2513797C2|1987-07-30|PHARMACEUTICAL COMPOSITION
    DE69920201T2|2005-09-29|COMPOSITIONS CONTAINING GLYCOL DERIVATIVES, ALCOHOLS AND VITAMIN D
    KR20080092373A|2008-10-15|Therapeutic compositions
    DE202014011208U1|2018-08-23|C1-INH compositions for the prevention and treatment of disorders associated with C1-esterase inhibitor deficiency
    DE10355251A1|2005-06-23|Water-based pharmaceutical preparation for treatment of tumors has active ingredient effective against receptor of endothelial growth factor receptor
    EP1663141B1|2007-03-21|Aqueous pharmaceutical solution containing oxymetazoline and/or xylometazoline
    DE60132798T2|2009-02-12|COMPOSITION OF A SODIUM CHANNEL BLOCKING COMPOUND
    DE60110185T2|2006-03-09|Composition and method for parenteral administration of ibuprofen D, L-, or L-lysinate
    DE10133394A1|2003-01-30|Liquid formulation containing cetuximab
    AT515356B1|2015-11-15|Stable alcoholic solution of alprostadil
    DE19900054A1|2000-07-06|Taxane-containing stable and sterile emulsion and process for their preparation
    EP2142169B1|2011-10-26|Aqueous pharmaceutical preparation
    DE60101979T2|2005-01-05|Solution containing N- [O- | benzoyl] glycine monosodium salt tetrahydrate and drug containing this solution
    WO2017015692A1|2017-02-02|Concentrate containing alprostadil
    DE60122384T2|2007-08-16|PROCESS FOR PREPARING A STABLE PHARMACEUTICAL FORM OF PACLITAXEL
    DE69922252T2|2005-12-01|PARENTERAL SOLUTIONS CONTAINING PROPOFOL | AND 2.5-DI-0-METHYL-1.4; 3.6-DIANHYDRO-D-GLUCITOL AS SOLVENT
    EP3360539A1|2018-08-15|Pharmaceutical formulation
    DE202012013584U1|2018-01-15|Pharmaceutical formulation containing curcumin
    WO2017015690A1|2017-02-02|Concentrate containing alprostadil
    DE3128579A1|1982-08-19|INJECTABLE PHARMACEUTICAL PREPARATIONS
    US11097023B1|2021-08-24|Pre-filled syringe containing sugammadex
    DE20221679U1|2006-11-23|Assembly comprising aqueous solution of oxaliplatin, useful for treating colorectal cancer, in glass bottle having specific volume to surface area ratio for improved stability
    DE3208505A1|1982-10-21|MEDIUM CONTAINING A LYOPHILIZED PENICILLINE DERIVATIVE
    同族专利:
    公开号 | 公开日
    EP3099330B1|2018-03-14|
    RU2016135034A|2018-03-01|
    EP3099330A1|2016-12-07|
    WO2015113094A1|2015-08-06|
    MX369244B|2019-11-01|
    RU2016135034A3|2018-05-11|
    JP2017507172A|2017-03-16|
    EP3395367A1|2018-10-31|
    MX2016009458A|2017-04-25|
    AT515356B1|2015-11-15|
    BR112016016469A8|2018-01-30|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3927197A|1974-04-19|1975-12-16|Pfizer|Tertiary alcohol stabilized E-series prostaglandins|
    CH635513A5|1977-05-12|1983-04-15|Sankyo Co|Process for the preparation of stable preparations of prostaglandins E|
    EP0089768A1|1982-03-22|1983-09-28|Upjohn Limited|Compositions containing prostaglandins|
    JPH0383925A|1989-08-29|1991-04-09|Hisamitsu Pharmaceut Co Inc|Prostaglandin e1-containing pharmaceutical for external use|
    UA78432C2|2005-08-09|2007-03-15|Закрите Акціонерне Товариство Науково-Виробничий Центр "Борщагівський Хіміко-Фармацевтичний Завод"|Composition for treating ischemic and pyo-necrotic lesions of lower limbs in diabetic angiopathies|
    CN102351767A|2011-09-20|2012-02-15|海南美兰史克制药有限公司|Alprostadil compound and preparation method thereof|
    KR100453803B1|1999-07-29|2004-10-20|환인제약 주식회사|Alprostadil-containing compositions for external use|
    WO2009093650A1|2008-01-24|2009-07-30|Techno Guard Co. Ltd.|Prostaglandin-containing fat emulsion and method for producing the same|
    WO2012133554A1|2011-03-31|2012-10-04|富士フイルム株式会社|Fat emulsion containing prostaglandin|
    CN102688203A|2012-06-06|2012-09-26|杭州澳亚生物技术有限公司|Alprostadil freeze-dried powder injection and preparation method thereof|
    CN103110579B|2013-02-20|2014-12-10|北京德立福瑞医药科技有限公司|Alprostadil injection|RU2695068C1|2018-06-26|2019-07-19|Общество с ограниченной ответственностью "Гурус БиоФарм"|Agent for treating chronic obliterating peripheral vascular diseases based on prostaglandin|
    法律状态:
    2021-09-15| MM01| Lapse because of not paying annual fees|Effective date: 20210130 |
    优先权:
    申请号 | 申请日 | 专利标题
    ATA50063/2014A|AT515356B1|2014-01-30|2014-01-30|Stable alcoholic solution of alprostadil|ATA50063/2014A| AT515356B1|2014-01-30|2014-01-30|Stable alcoholic solution of alprostadil|
    PCT/AT2015/050029| WO2015113094A1|2014-01-30|2015-01-29|Stable alcoholic solution of alprostadil|
    JP2016567105A| JP2017507172A|2014-01-30|2015-01-29|Stable alcohol solution of alprostadil|
    RU2016135034A| RU2016135034A3|2014-01-30|2015-01-29|
    EP18150928.2A| EP3395367A1|2014-01-30|2015-01-29|Stable alcoholic solution of alprostadil|
    EP15709819.5A| EP3099330B1|2014-01-30|2015-01-29|Stable alcoholic solution of alprostadil|
    MX2016009458A| MX369244B|2014-01-30|2015-01-29|Stable alcoholic solution of alprostadil.|
    BR112016016469-5A| BR112016016469B1|2014-01-30|2015-01-29|LIQUID PHARMACEUTICAL COMPOSITION, PARENTERAL COMPOSITION, PROCESS FOR THE PRODUCTION OF SUCH PHARMACEUTICAL COMPOSITIONS AND KIT OF PARTS|
    [返回顶部]